Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Rafael Holdings, Inc. Class B Common Stock

RFL

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Last trade $0.9205
Day change -$0.0496 (-5.11%)
Day range $0.87 – $1.00
Volume 75,431
Market cap $51M

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$50.62M
Price / earnings
—
Price / book
0.76×
Price / sales
57.92×
EV / sales
33.36×
EV / EBITDA
-0.88×

Profitability

Earnings per share
-$0.57
Return on assets
-35.68%
Return on equity
-44.69%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.01×
Current ratio
2.35×
Quick ratio
2.32×
Cash ratio
2.01×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$29.99M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RFL, quarterly periods
Line itemQ4 FY2026 Jul 31, 2026Q3 FY2026 Apr 30, 2026Q2 FY2026 Jan 31, 2026Q1 FY2026 Oct 31, 2025Q4 FY2025 Jul 31, 2025Q3 FY2025 Apr 30, 2025Q2 FY2025 Jan 31, 2025Q1 FY2025 Oct 31, 2024
Revenue$244K$179K$211K$240K$350K$362K$77K$128K
Cost of revenue$13K$8K$12K$9K$19K$40K$38K$37K
Gross profit$231K$171K$199K$231K$331K$322K$39K$91K
Selling, general and administrative$2.44M$2.14M$2.27M$2.84M$5.5M$3.17M$2.59M$2.52M
Research and development$7.47M$4.85M$4.53M$7.48M$7.55M$3M$947K$1.33M
Total operating expenses$9.96M$7.04M$6.85M$10.37M$13.09M$6.24M$6.68M$3.94M
Operating income-$9.73M-$6.87M-$6.66M-$10.14M-$12.76M-$5.91M-$6.64M-$3.84M
Interest expense-$6K-$6K-$161K-$160K-$168K-$165K-$163K-$162K
Income before taxes-$9M-$2.89M-$6.28M-$9.79M-$12.23M-$6.46M-$5.31M-$9.2M
Income taxes-$65K$6K$48K$10K-$174K-$2.41M$20K$12K
Net income-$8.93M-$2.9M-$6.33M-$9.8M-$12.05M-$4.05M-$5.33M-$9.21M
Net income attributable to common shareholders-$9.18M-$4.23M-$6.42M-$9.82M-$12.09M-$4.78M-$4.64M-$9.01M
EBITDA-$9.68M-$6.82M-$6.6M-$10.09M-$12.71M-$5.85M-$3.5M-$3.76M
Basic earnings per share-$0.18-$0.08-$0.13-$0.19-$0.27-$0.19-$0.19-$0.37
Diluted earnings per share-$0.18-$0.08-$0.13-$0.19-$0.27-$0.19-$0.19-$0.37

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Rafael Holdings, Inc. - RFL

Pomerantz LLP is investigating securities fraud claims on behalf of investors of Rafael Holdings, Inc. after the company announced that its Phase 3 clinical trial for Trappsol Cyclo failed to achieve statistical significance on its primary endpoint. Rafael's stock price fell 34.98% following the announcement on September 30, 2026. The law firm is also investigating similar claims against FMC Corporation and Neogen Corporation.

The Motley Fool

BOS Reports 36 Percent Revenue Jump

B.O.S. Better Online Solutions reported strong Q2 2025 results with 36% revenue growth and 53% net income increase, driven primarily by defense sector demand and a robust supply chain division.

Benzinga

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Rafael Holdings reported a net loss for the second quarter and first six months of fiscal year 2025, primarily due to unrealized losses on its investment in Cyclo Therapeutics. The company is focused on Cyclo's lead clinical program Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 following the planned merger with Cyclo Therapeutics.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Dec 18, 2009$0.0202Dec 31, 2009unknown
Jun 19, 2009$0.0145Jun 30, 2009unknown
Mar 20, 2009$0.0242Mar 31, 2009unknown
Dec 19, 2008$0.1406Dec 31, 2008unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.